Literature DB >> 9541525

The PTH-calcium relationship during a range of infused PTH doses in the parathyroidectomized rat.

I Berdud1, A Martin-Malo, Y Almaden, P Aljama, M Rodriguez, A J Felsenfeld.   

Abstract

To establish the PTH dosage that maintains normal mineral homeostasis in the PTX rat, a series of doses of rat 1-34 PTH were infused via a subcutaneously implanted miniosmotic pump. The doses were 0, 0.011, 0.022, 0.044, and 0.11 microg/100 g/hour. After 48 hours, serum calcium ranged from 5.56 +/- 0.02 to 16.29 +/- 0.25 mg/dl, ANOVA P < 0.001, and serum phosphorus from 12.49 +/- 0.03 to 5.33 +/- 0.34 mg/dl, ANOVA P < 0.001. By post hoc test, the serum calcium level was different (P < 0.05) at every PTH dose; the serum phosphorus level was different (P < 0.05) at every PTH dose except between the two highest doses. The PTH dosage that produced a normal serum calcium (10.09 +/- 0.10 mg/dl) and phosphorus (6.90 +/- 0.18 mg/dl) was 0.022 microg/100 g/hour. The relationship between increasing doses of PTH and both serum calcium and phosphorus was curvilinear and the calcium-phosphorus product was remarkably constant from a serum calcium of 7-13 mg/dl. The increase in serum calcium and the decrease in serum phosphorus were more rapid at lower than at higher PTH doses so that for both, an asymptote was reached. At the highest serum calcium values, the calcium-phosphorus product increased and in individual rats, an increase in serum phosphorus was associated with a decrease in serum calcium. In summary, this study shows that (1) for rat 1-34 PTH, the normal replacement dose in the PTX rat with normal renal function on a normal diet is 0.022 microg/100 g/hour; (2) the relationship between PTH and both serum calcium and phosphorus is curvilinear, and an asymptote is reached for both; and (3) the calcium-phosphorus product is remarkably constant as the serum calcium increases from 7 to 13 mg/dl and only increased during marked hypercalcemia when serum phosphorus did not decrease further or even tended to increase.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9541525     DOI: 10.1007/s002239900460

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  5 in total

1.  Interdependence of cardiac iron and calcium in a murine model of iron overload.

Authors:  Maya Otto-Duessel; Casey Brewer; John C Wood
Journal:  Transl Res       Date:  2010-12-13       Impact factor: 7.012

2.  Diphtheria Toxin- and GFP-Based Mouse Models of Acquired Hypoparathyroidism and Treatment With a Long-Acting Parathyroid Hormone Analog.

Authors:  Ruiye Bi; Yi Fan; Kelly Lauter; Jing Hu; Tomoyuki Watanabe; Jim Cradock; Quan Yuan; Thomas Gardella; Michael Mannstadt
Journal:  J Bone Miner Res       Date:  2016-01-20       Impact factor: 6.741

Review 3.  The laboratory rat as an animal model for osteoporosis research.

Authors:  Pavlos P Lelovas; Theodoros T Xanthos; Sofia E Thoma; George P Lyritis; Ismene A Dontas
Journal:  Comp Med       Date:  2008-10       Impact factor: 0.982

4.  Trabecular bone organoids: a micron-scale 'humanised' prototype designed to study the effects of microgravity and degeneration.

Authors:  Alexandra Iordachescu; Erik A B Hughes; Stephan Joseph; Eric J Hill; Liam M Grover; Anthony D Metcalfe
Journal:  NPJ Microgravity       Date:  2021-05-21       Impact factor: 4.415

5.  The vitamin D, ionised calcium and parathyroid hormone axis of cerebral capillary function: therapeutic considerations for vascular-based neurodegenerative disorders.

Authors:  Virginie Lam; Ryusuke Takechi; Menuka Pallabage-Gamarallage; Corey Giles; John C L Mamo
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.